Nov 2020 $18 M No. 6 $10 to $50 million 25
Dipexium Pharmaceuticals, LLC: Raise no. 6, Nov 2020 × Investors in this round 25 investors had bought by the notice of Nov 30, 2020: 25 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $18 M of $18 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $1,020,325
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Michael J. Valentino · Executive Officer, Director Natasha Giordano · Executive Officer, Director Rita O'Connor · Executive Officer Anthony J. Bartsh · Director Gary J. Balkema · Director John W. Hadden II · Director Kirk J. Calhoun · Director Robert J. Casale · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Raymond James & Associates, Inc. (CRD 705) · Saint Petersburg, Florida Sold in FL, GA, IL, NJ, NY, OH, TX, VA, VT Signed by Rita O'Connor, Chief Financial Officer. Source: SEC Form D, newest notice filed Nov 30, 2020. Read the notice at the SEC .
equity, options SEC May 2020 $8 M No. 5 $2 to $10 million 3
Dipexium Pharmaceuticals, LLC: Raise no. 5, May 2020 × Investors in this round 3 investors had bought by the notice of May 29, 2020: 3 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $8 M of $8 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $120,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Michael J. Valentino · Executive Officer, Director Natasha Giordano · Executive Officer, Director Rita O'Connor · Executive Officer Anthony J. Bartsh · Director Gary J. Balkema · Director John W. Hadden II · Director Kirk J. Calhoun · Director Robert J. Casale · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Raymond James & Associates, Inc. (CRD 705) · Saint Petersburg, Florida Sold in NY Signed by Rita O'Connor, Chief Financial Officer. Source: SEC Form D, newest notice filed May 29, 2020. Read the notice at the SEC .
equity, options SEC Feb 2019 $15 M No. 4 $10 to $50 million 2
Dipexium Pharmaceuticals, LLC: Raise no. 4, Feb 2019 × Investors in this round 2 investors had bought by the notice of Mar 4, 2019: 2 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $15 M of $15 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $1,050,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Efthymios Deliargyris · Executive Officer Michael J. Valentino · Executive Officer, Director Natasha Giordano · Executive Officer, Director Rita O'Connor · Executive Officer Gary J. Balkema · Director John W. Hadden II · Director Kirk J. Calhoun · Director Robert J. Casale · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round JMP Securities LLC (CRD 22208) · New York, New York Sold in CA Signed by Rita O'Connor, Chief Financial Officer. Source: SEC Form D, newest notice filed Mar 4, 2019. Read the notice at the SEC .
equity, options SEC Jun 2017 $18 M No. 3 $10 to $50 million 37
Dipexium Pharmaceuticals, LLC: Raise no. 3, Jun 2017 × Investors in this round 37 investors had bought by the notice of Jun 28, 2017: 37 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $18 M of $18 M offered
Smallest investment taken no minimum stated
What was sold options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue No revenue
Sales commissions $1,191,512
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice David J. Jorden · Executive Officer Gary J. Mossman · Executive Officer Michael J. Valentino · Executive Officer, Director Natasha J. Giordano · Executive Officer, Director David J. Luci · Director Gary J. Balkema · Director John J. Hadden · Director Kirk J. Calhoun · Director Robert J. Casale · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Raymond James & Associates, Inc. (CRD 705) · St. Petersberg, Florida Sold in CA, FL, NJ, NY, TX, VT Janney Montgomery Scott LLC (CRD 463) · Philadelphia, Pennsylvania Sold in CA, FL, NJ, NY, TX, VT Remarks in the notice On fees: “Sales commission reflects amount paid in connection with (i) this offering and (ii) a concurrent public offering of common stock, consisting of a $1,091,512 fee and expenses up to $100,000 (including legal fees up to $75,000).”On the use of proceeds: “No proceeds are proposed to be used for payments to such persons other than ordinary salary expenses that may be paid out of working capital.”Signed by David Jorden, Acting CFO. Source: SEC Form D, newest notice filed Jun 28, 2017. Read the notice at the SEC .
options SEC Jul 2013 $3 M No. 2 $2 to $10 million 28
Dipexium Pharmaceuticals, LLC: Raise no. 2, Jul 2013 × Investors in this round 28 investors had bought by the notice of Jul 22, 2013: 28 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $3 M of $6 M offered; $3 M still to sell
Smallest investment taken $25,000
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them
Meant to last a year or less
Issuer's revenue No revenue
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks payments to its own people as estimates
The company Limited Liability Company, incorporated in Delaware People named in the notice David P. Luci · Executive Officer, Director, Promoter Robert J. DeLuccia · Executive Officer, Director, Promoter Christopher J. Coughlin · Director Ellen J. Zaroff · Director Jack J. Dean · Director John J. Leone · Director John J. Terrana · Director Michael J. Duffy · Director Steven J. Hurd · Director William J. McSherry, Jr. · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by David P. Luci, Managing Partner. Source: SEC Form D, newest notice filed Jul 22, 2013. Read the notice at the SEC .
equity, options SEC Jul 2010 $3 M No. 1 $2 to $10 million 34
Dipexium Pharmaceuticals, LLC: Raise no. 1, Jul 2010 × Investors in this round 34 investors had bought by the notice of Nov 7, 2011: 34 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $3 M of $3 M offered; $0 M still to sell
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them
Meant to last a year or less
Issuer's revenue No revenue
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks sales commissions and payments to its own people as estimates
The company Limited Liability Company, incorporated in Delaware People named in the notice David P. Luci · Executive Officer, Director, Promoter Robert J. DeLuccia · Executive Officer, Director, Promoter Jack J. Dean · Director John J. Terrana · Director Milos J. Koterec · Director Steven D. Hurd · Director William J. McSherry, Jr. · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On fees: “Issuer may pay fees of 6% for any investor introduced by a placement agent.”Signed by David P. Luci, Managing Partner. Source: SEC Form D and 1 amendment, newest notice filed Nov 7, 2011. Read the notice at the SEC .
equity, options SEC